At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 231 enrolled
Drug / intervention
Eptinezumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Delayed-Start Study to Evaluate the Efficacy and Safety of Eptinezumab in Patients With Episodic Cluster Headache
In Brief
A Phase 3 clinical trial evaluating Eptinezumab and Placebo for Cluster Headache, Episodic. Completed, enrolled 231 participants across 120 sites in 19 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy of eptinezumab in participants with episodic Cluster Headache (eCH)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCluster Headache, Episodic
CountriesBelgium, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Italy, Japan, Netherlands, Norway, Portugal, Russia, Spain, Sweden, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
Enrollment StartDec 2020
First PostedDec 2020
Primary CompletionJun 2023
Study CompletionOct 2023
TodayJul 2026
First PostedDec 30, 2020
Enrollment StartDec 23, 2020
Primary CompletionJun 14, 2023
Study CompletionOct 5, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.5 years ago
Interventions
Eptinezumabdrug
Eptinezumab - concentrate for solution for infusion, intravenously
Placebodrug
Placebo - 100 milliliters (mL) of 0.9% normal saline, intravenously